Oncology Pharma Announces Extension of Letter of Intent with Kalos Therapeutics, Retained an Interim CEO and Approval of Reverse Stock Split
27. August 2020 09:00 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Aug. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it has extended its Letter of Intent with Kalos Therapeutics....
Oncology Pharma and Kalos Therapeutics Expand Licensing Agreement for Exploring Kalos's Anti-Cancer Lead Drug in Treating COVID-19
06. April 2020 08:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, April 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE ‒ Oncology Pharma, Inc. (OTCPK: ONPH) and Kalos Therapeutics (“Kalos”) announced today that the companies amended the terms of...
Oncology Pharma Continues Licensing Agreement with NanoSmart
11. März 2020 08:00 ET
|
Oncology Pharma, Inc.
San Francisco, CA, March 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it is continuing its relationship with NanoSmart...
Oncology Pharma, Inc. Narrows Focus on Funding Efforts
28. Januar 2020 09:29 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Jan. 28, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) would like to inform investors that it has completed its relationship with Tulynode...
CORRECTION: Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Investment Partners, Ltd
26. Dezember 2019 22:15 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Dec. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
Oncology Pharma Receives LOI for Financing for US$ 38.4M from SCP Partners Ltd
23. Dezember 2019 07:00 ET
|
Oncology Pharma, Inc.
SAN FRANCISCO, CA, Dec. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – ONCOLOGY PHARMA, INC. (OTCPK: ONPH) is pleased to announce that it has received a letter of intent dated December 20th to...
Oncology Pharma Signs Letter of Intent to Acquire a Significant Stake in Diagnomics, Inc.
11. Dezember 2019 18:42 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Dec. 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTC: ONPH) announced today that it has signed a Letter of Intent (LOI) to acquire at least a 50% stake...
Oncology Pharma and Ribera Solutions Signed a Licensing Agreement for the Use of Ribera's Clinical Trials Platform, Connect2Med
06. November 2019 07:30 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma Inc. (OTCPK: ONPH) is pleased to announce that it has entered into an agreement with Ribera for its clinical...
Oncology Pharma Appoints Dr. Vijay Mahant as the Chief Scientific Officer and Chief Operating Officer
15. Oktober 2019 06:30 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. is pleased to announce today that Vijay Mahant (M.S, Ph.D.) has been appointed as the Chief Scientific...
Oncology Pharma Elects Dr. Stefan Gruenwald (MD, PhD) to its Board of Directors
08. Oktober 2019 06:30 ET
|
Oncology Pharma, Inc.
San Francisco, CA, Oct. 08, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma Inc. is pleased and honored to announce that Stefan Gruenwald (MD, PhD), cofounder and president of...